Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer

Ähnliche Einträge

• Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer
  von: Jacob Hanna, et al.
  Veröffentlicht: (2026)
• Lymph node dissection during cystectomy for non‐muscle‐invasive bladder cancer: A systematic review
  von: Sean Lim, et al.
  Veröffentlicht: (2026)
• Time to abandon routine urine analysis prior to Bacillus Calmette–Guérin administration in asymptomatic patients
  von: Antti Nummi, et al.
  Veröffentlicht: (2025)
• Real‐world use of maintenance bacillus Calmette‐Guérin therapy in patients with non‐muscle‐invasive bladder cancer in Japan: ASUKA study
  von: Makito Miyake, et al.
  Veröffentlicht: (2025)
• Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: A meta‐analysis
  von: Sean Lim, et al.
  Veröffentlicht: (2024)